SMAIO SA (ALSMA.PA) Fundamental Analysis & Valuation

EPA:ALSMA • FR0014005I80

6.8 EUR
-0.25 (-3.55%)
Last: Mar 9, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This ALSMA.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Overall ALSMA gets a fundamental rating of 4 out of 10. We evaluated ALSMA against 65 industry peers in the Health Care Equipment & Supplies industry. ALSMA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALSMA is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

1

1. ALSMA.PA Profitability Analysis

1.1 Basic Checks

  • In the past year ALSMA has reported negative net income.
  • ALSMA had a negative operating cash flow in the past year.
  • In the past 5 years ALSMA reported 4 times negative net income.
  • In multiple years ALSMA reported negative operating cash flow during the last 5 years.
ALSMA.PA Yearly Net Income VS EBIT VS OCF VS FCFALSMA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M

1.2 Ratios

  • ALSMA's Return On Assets of -13.39% is on the low side compared to the rest of the industry. ALSMA is outperformed by 72.31% of its industry peers.
  • The Return On Equity of ALSMA (-25.00%) is worse than 70.77% of its industry peers.
Industry RankSector Rank
ROA -13.39%
ROE -25%
ROIC N/A
ROA(3y)0.22%
ROA(5y)-14.26%
ROE(3y)-3.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALSMA.PA Yearly ROA, ROE, ROICALSMA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

  • ALSMA's Gross Margin of 83.83% is amongst the best of the industry. ALSMA outperforms 95.38% of its industry peers.
  • ALSMA's Gross Margin has declined in the last couple of years.
  • ALSMA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.54%
GM growth 5Y-12.33%
ALSMA.PA Yearly Profit, Operating, Gross MarginsALSMA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ALSMA.PA Health Analysis

2.1 Basic Checks

  • ALSMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ALSMA has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ALSMA has less shares outstanding
  • Compared to 1 year ago, ALSMA has an improved debt to assets ratio.
ALSMA.PA Yearly Shares OutstandingALSMA.PA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
ALSMA.PA Yearly Total Debt VS Total AssetsALSMA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

  • An Altman-Z score of 3.97 indicates that ALSMA is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.97, ALSMA is doing good in the industry, outperforming 69.23% of the companies in the same industry.
  • A Debt/Equity ratio of 0.33 indicates that ALSMA is not too dependend on debt financing.
  • ALSMA has a Debt to Equity ratio (0.33) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Altman-Z 3.97
ROIC/WACCN/A
WACC7.9%
ALSMA.PA Yearly LT Debt VS Equity VS FCFALSMA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

  • ALSMA has a Current Ratio of 2.90. This indicates that ALSMA is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of ALSMA (2.90) is better than 81.54% of its industry peers.
  • ALSMA has a Quick Ratio of 2.50. This indicates that ALSMA is financially healthy and has no problem in meeting its short term obligations.
  • ALSMA has a Quick ratio of 2.50. This is amongst the best in the industry. ALSMA outperforms 90.77% of its industry peers.
Industry RankSector Rank
Current Ratio 2.9
Quick Ratio 2.5
ALSMA.PA Yearly Current Assets VS Current LiabilitesALSMA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ALSMA.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 36.05% over the past year.
  • The Revenue has grown by 130.31% in the past year. This is a very strong growth!
  • The Revenue has been growing by 69.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)36.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.48%
Revenue 1Y (TTM)130.31%
Revenue growth 3Y37.17%
Revenue growth 5Y69.73%
Sales Q2Q%126.03%

3.2 Future

  • Based on estimates for the next years, ALSMA will show a very strong growth in Earnings Per Share. The EPS will grow by 43.73% on average per year.
  • The Revenue is expected to grow by 36.55% on average over the next years. This is a very strong growth
EPS Next Y35%
EPS Next 2Y41.42%
EPS Next 3Y38.6%
EPS Next 5Y43.74%
Revenue Next Year67.27%
Revenue Next 2Y51.06%
Revenue Next 3Y45.24%
Revenue Next 5Y36.55%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALSMA.PA Yearly Revenue VS EstimatesALSMA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10M 20M 30M
ALSMA.PA Yearly EPS VS EstimatesALSMA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2027 2028 0 0.2 -0.2 0.4 -0.4 0.6 0.8

More info and screens

Find the best growth stocksShow best growing peers

1

4. ALSMA.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALSMA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALSMA.PA Price Earnings VS Forward Price EarningsALSMA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALSMA.PA Per share dataALSMA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ALSMA's earnings are expected to grow with 38.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y38.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALSMA.PA Dividend Analysis

5.1 Amount

  • ALSMA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALSMA.PA Fundamentals: All Metrics, Ratios and Statistics

SMAIO SA

EPA:ALSMA (3/9/2026, 7:00:00 PM)

6.8

-0.25 (-3.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners65.36%
Ins Owner ChangeN/A
Market Cap38.42M
Revenue(TTM)8.28M
Net Income(TTM)-1.85M
Analysts86
Price Target8.67 (27.5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.03%
PT rev (3m)4.94%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.96%
EPS NY rev (3m)-26.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-8%
Revenue NY rev (3m)-8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.64
P/FCF N/A
P/OCF N/A
P/B 5.19
P/tB 7.57
EV/EBITDA N/A
EPS(TTM)-0.35
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS1.47
BVpS1.31
TBVpS0.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.39%
ROE -25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.83%
FCFM N/A
ROA(3y)0.22%
ROA(5y)-14.26%
ROE(3y)-3.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.54%
GM growth 5Y-12.33%
F-Score5
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 149.37%
Cap/Sales 22.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.9
Quick Ratio 2.5
Altman-Z 3.97
F-Score5
WACC7.9%
ROIC/WACCN/A
Cap/Depr(3y)98.78%
Cap/Depr(5y)137.67%
Cap/Sales(3y)30.2%
Cap/Sales(5y)56.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.48%
EPS Next Y35%
EPS Next 2Y41.42%
EPS Next 3Y38.6%
EPS Next 5Y43.74%
Revenue 1Y (TTM)130.31%
Revenue growth 3Y37.17%
Revenue growth 5Y69.73%
Sales Q2Q%126.03%
Revenue Next Year67.27%
Revenue Next 2Y51.06%
Revenue Next 3Y45.24%
Revenue Next 5Y36.55%
EBIT growth 1Y34.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year78%
EBIT Next 3Y46.44%
EBIT Next 5Y44.66%
FCF growth 1Y-114.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-872.79%
OCF growth 3YN/A
OCF growth 5YN/A

SMAIO SA / ALSMA.PA FAQ

What is the fundamental rating for ALSMA stock?

ChartMill assigns a fundamental rating of 4 / 10 to ALSMA.PA.


Can you provide the valuation status for SMAIO SA?

ChartMill assigns a valuation rating of 1 / 10 to SMAIO SA (ALSMA.PA). This can be considered as Overvalued.


What is the profitability of ALSMA stock?

SMAIO SA (ALSMA.PA) has a profitability rating of 1 / 10.


What is the expected EPS growth for SMAIO SA (ALSMA.PA) stock?

The Earnings per Share (EPS) of SMAIO SA (ALSMA.PA) is expected to grow by 35% in the next year.